Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;33(6):e14234.
doi: 10.1111/dth.14234. Epub 2020 Sep 14.

Efficacy and safety of oral minoxidil in female androgenetic alopecia

Maria Vastarella  1 , Mariateresa Cantelli  1 , Angela Patrì  1 , Maria Carmela Annunziata  1 , Paola Nappa  1 , Gabriella Fabbrocini  1
Affiliations

Efficacy and safety of oral minoxidil in female androgenetic alopecia

Maria Vastarella et al. Dermatol Ther. 2020 Nov.

Abstract

Oral minoxidil (OM) has been reported to be effective for androgenetic alopecia (AGA). In this retrospective study, we share our experience of using OM for >24 weeks in 12 patients with female AGA (Ludwig scale I-3-III). Twelve women (aged 18-66 years; mean age 36.66 ± 18.79 years) with AGA (Ludwig scale I-3-III) were recruited. The starting dose of minoxidil was 0.50 mg daily; at 3 months, the dose was increased to 1.50 to 2 mg daily. Efficacy outcome measures were evaluated at baseline and after 24 weeks and included global clinical photography, quantitative digital videotrichoscopic assessment and quality-of-life evaluation. An overall improvement of 38% and 23% in hair density in the frontal and vertex area, respectively, was observed after 24 weeks. The quantitative digital videotrichoscopic evaluation highlighted a statistically significant improvement in the frontal area of the total average hair density and of the total number of hairs per unit area at 24 weeks (131.47 ± 36.11 vs 181.40 ± 57.38; P = .025 and 118.72 ± 32.61 vs 163.81 ± 51.82; P = .025, respectively). In conclusion, OM was effective and had an acceptable safety profile in treating female AGA. The low number of patients and retrospective design of this study are limitations.

Keywords: alopecia; hair disorder.

PubMed Disclaimer

References

REFERENCES

    1. Sinclair R, Trindade de Carvalho L, Ismail FF, Meah N. Treatment of male and female pattern hair loss with sublingual minoxidil: a retrospective case-series of 64 patients. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16616.
    1. Ramos PM, Sinclair RD, Kasprzak M, Miot HA. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: a randomised clinical trial. J Am Acad Dermatol. 2020;82(1):252-253. https://doi.org/10.1016/j.jaad.2019.08.060.
    1. Jha A, Sonthalia S, Zeeshan MD, Vinay K. Efficacy and safety of very low dose oral minoxidil 1.25mg in male androgenetic alopecia. J Am Acad Dermatol. 2020:S0190-9622(20)31005-7. https://doi.org/10.1016/j.jaad.2020.05.129.
    1. Gomolin A, Litvinov IV, Netchiporouk E. Oral minoxidil: a possible new therapy for androgenetic alopecia. J Cutan Med Surg. 2020;24(1):88-89. https://doi.org/10.1177/1203475419879887.
    1. Sinclair R, Patel M, Dawson TL Jr, et al. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Br J Dermatol. 2011;165(suppl 3):12-18. https://doi.org/10.1111/j.1365-2133.2011.10630.x.

LinkOut - more resources